not used title
not used title
Two studies released last month reveal how hospitals across the country mark up the price of medicines and deliver a growing share of provider-administered medicines, resulting in higher costs that are often passed onto patients.
- A study published in the American Journal of Managed Care examined the price of care at more than 3,200 hospitals in all 50 states and found substantial charge variation by hospital across oncology services. “What we found in the marketplace is that over one quarter of the medical centers that provide cancer services are charging more than 5.1 times the Medicare allowable amount, and in some cases the centers are charging more than 15 times the Medicare allowable amount,” noted lead author Martin Makary, MD, MPH, a cancer surgeon at Johns Hopkins Hospital. The study found the most significant markups at hospitals with for-profit status for medical oncology services and hospitals with prestige status for radiology and pathology.
- A separate study published by JAMA Oncology showed a staggering difference between the cost of chemotherapy depending on the site of care. The research found that the same care provided in a hospital outpatient department cost roughly double than in a physician’s office for commercially insured patients. For example, the average spending on chemotherapy medicine was $1,466 for treatments administered in a physician’s office, but hospitals receive $3,799 ($2,333 more). Despite the cost disparities, the study also concluded that the delivery of chemotherapy is trending towards hospitals and away from physicians’ offices. In 2004, only 6 percent of infusions occurred in the hospital, compared to 43 percent in 2014.
Provider consolidation and markups increases costs for the health care system and, ultimately, for patients. One key driver of this consolidation is the 340B program, which allows qualifying hospitals to obtain steep discounts for prescription medicines. Current program guidance allows 340B hospitals to extend their 340B eligibility to independent physician practices they’ve purchased. These hospitals can then be reimbursed by commercial payers for medicines administered at these offices at the regular negotiated rate – and pocket any different between their reimbursement and the 340B discounted price.
A recent study in the New England Journal of Medicine concluded that financial incentives created by the 340B program have led 340B eligible hospitals to alter their behavior by acquiring more physician practices and increasing hospital administration of drugs. Congress created the 340B program to support safety net providers, yet the analysis found no evidence 340B hospitals use revenue derived from the program to “invest in safety net providers, provide more inpatient care to low-income patients, or enhance care for low-income groups in ways that would reduce mortality.”
As has been discussed in prior Catalyst blogs, the Moran Company found hospitals receive, on average, more than 250 percent what they paid for a medicine after negotiations with commercial payers, even without accounting for discounts provided through the 340B program. In these cases, a hospital is ultimately paid more than the biopharmaceutical company who brought the medicine to market.
As insurers continue to raise patients’ share of health care spending, and hospitals buy up community physicians, these high prices increase patient costs. For underinsured patients or those who need out-of-network services, the impact can be even greater. Patients, especially those fighting cancer, rarely have a choice in where they receive their care, as the urgency of their diagnoses limits their ability to seek other options.
To learn more, visit LetsTalkAboutCost.org.
Joe Vandigo
Joe Vandigo is a former director in the Policy and Research department at PhRMA.
Joe Vandigo
ICYMI: Hospital consolidation is driving up health care costs
August 27, 2026
New study: HPV vaccination helps prevent cervical cancer deaths
July 21, 2026
340B’s reality: A booming business for hospitals, pharmacies and corporate giants
June 25, 2026
America's cancer research progress is real and worth protecting
May 28, 2026
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
May 26, 2026
A program off track: How 340B drives both hospital consolidation and system gaming
April 27, 2026
Washington Post Editorial Board says 340B has become “corporate welfare”
April 27, 2026
Hospitals drive nearly 80% of the U.S. health spending gap
March 25, 2026
Congress should look under the hood of 340B, hospitals don't want them to
March 19, 2026
340B hospitals buy low and sell high, a new analysis shows
March 12, 2026
New report from Minnesota: 340B is generating billions for big hospitals
March 9, 2026
Advancing patient care: A look at new medicines approved in 2025
January 30, 2026
CAREs 2025: Supporting community-based solutions that improve access to medicines
January 22, 2026
New analysis finds 340B hospitals push patients toward costly care to boost profits
January 21, 2026
Price setting policies put cancer gains in jeopardy
January 16, 2026
Latest analysis from Ohio exposes growing abuses of the 340B markup program
July 7, 2025
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
February 25, 2025
Guest Perspective: Prioritize Innovative Care
February 11, 2025
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
February 3, 2025
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
November 13, 2024
Reimagining patient access through meaningful policy reform
November 5, 2024
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
October 30, 2024
The importance of partnership: A conversation with Takeda
October 10, 2024
Don’t put the government between patients and their medicines
August 7, 2024
The future of oncology R&D lies in policymakers’ hands
July 8, 2024
Showcasing the promise of biopharma at ASCO 2024
June 28, 2024
The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026
June 25, 2024
Ongoing federal probes shed light on PBM and insurer practices
May 20, 2024
Critics repeat same, misleading narrative on potential “costs” of new medicines
May 7, 2024
WTAS: The consequences of consolidation and vertical integration
May 6, 2024
Championing cancer equity: Our drive for healthier AANHPI communities
May 1, 2024
Insurance data: PBM reform has no material impact on premiums
April 24, 2024
What recent rhetoric on the cost of diabetes and anti-obesity medicines gets wrong
April 9, 2024
3 Takeaways from POLITICO’s Health Care Summit
April 3, 2024
The impact of innovative medicines: A caregiver's perspective
March 26, 2024
Four years later, Maryland board still hasn’t delivered for patients
February 12, 2024
PhRMA awards $250,000 to community-based projects to improve equitable cancer outcomes
February 9, 2024
Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients
February 7, 2024
Three things to know about antibody drug conjugates
February 2, 2024
When it comes to the future of innovation, the ball is in policymakers’ court
January 22, 2024
ICYMI: When middlemen get in the way, it’s the patients who lose
December 5, 2023
The IRA’s pill penalty threatens the future of oncology R&D
November 16, 2023
ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails
November 15, 2023
New Report: 1,600 cancer treatments and vaccines in clinical development
November 9, 2023
One year to Election Day: Four voter priorities to watch
November 6, 2023
ICYMI: Scott LaGanga and Matt Salo deliver a State of the Industry Report
October 25, 2023
R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot
October 18, 2023
ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs
September 28, 2023
Medicare Prescription Payment Plan will benefit patients if implemented correctly
September 21, 2023
By the Numbers: 340B continues to climb in profits, dwindle with patient support
September 13, 2023
New PhRMA ad exposes yet another way PBMs get between patients and their medicines
September 5, 2023
Watch: New video series spotlights advances in biopharmaceutical science
August 24, 2023
AARP’s latest misleading report
August 11, 2023
New report: Hospitals mark up medicine prices 500%
August 2, 2023
read more
August 2, 2023
Three things to know from the latest Patient Experience Survey
July 20, 2023
Key considerations as Congress works towards PAHPA reauthorization
July 12, 2023
Between hope and despair: Improving cancer outcomes
July 11, 2023
New report shows high-impact R&D happens after cancer medicines are first approved
July 10, 2023
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
June 22, 2023
ASCO 2023: Protecting our progress in the fight against cancer
June 15, 2023
Highlights from ASCO 2023
June 8, 2023
ICYMI: PBM exec admits choosing profits over patients
June 2, 2023
Insulin: Key Facts on Access & Affordability
May 10, 2023
4 key facts on medicine prices and spending
May 9, 2023
4 Things to know about PhRMA’s new 50-state poll
May 4, 2023
Americans want state policymakers to lower out-of-pocket costs
May 1, 2023
Three facts about health care spending
April 25, 2023
Nonprofit hospitals fall short on community benefit, studies show
April 24, 2023
States can support access to medicine as COVID-19 Public Health Emergency ends
April 5, 2023
Arkansas puts patients first with new share the savings law
April 4, 2023
Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care
March 29, 2023
IRA Impacts: Cancer treatment research and development
March 23, 2023
Why Congress should prioritize fixing the 340B program
March 2, 2023
Holding pharmacy benefit managers accountable
February 23, 2023
Stopping pharmacy benefit managers from “gaming the system”
February 22, 2023
What they are saying: Nonprofit hospitals are gaming the system at the expense of patients
February 21, 2023
Senate hearing to examine bipartisan reforms to rein in middlemen
February 16, 2023
State policymakers can protect American innovation and help Americans live longer, healthier lives
February 9, 2023
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines
January 31, 2023
ICYMI: Cancer death rate continues to decline due to treatment advances
January 25, 2023
Novel medicines approved in 2022 offer increased treatment options for patients
January 23, 2023
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
January 19, 2023
Study finds hepatitis C cure saved Medicaid $15 billion
January 5, 2023
340B program continues to drive shift in care to more expensive hospital settings
December 15, 2022
In their own words: Financial barriers exacerbate access challenges for insured Americans
December 8, 2022
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
December 1, 2022
Putting Delaware patients first: Protecting Patient Assistance Programs
November 22, 2022
New data show how insurers and middlemen shift Rx costs onto patients
November 16, 2022
ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research
November 8, 2022
Protecting treatment advances for breast cancer
October 31, 2022
In their own words: Insured Americans struggle to navigate complex coverage
October 26, 2022
Many seniors are paying more for Part D medicines than their insurer
October 18, 2022
New comments outline ways to protect patients from health plans and PBMs who profit from patient assistance
October 7, 2022
Busting 3 Myths About Copay Coupons
October 5, 2022
Mental Illness Awareness Week – A time for reflection
October 3, 2022
A key fact the White House is reluctant to admit
September 27, 2022
A key fact the White House is reluctant to admit
September 27, 2022
Navigating the patient experience: Burdens and barriers standing between patients and their care
September 12, 2022
Making coupons count for patients at the pharmacy counter
August 25, 2022
Making coupons count for patients with HIV
August 8, 2022
The Senate’s latest price setting proposal will undermine: Our health care system
July 28, 2022
The Senate’s latest price setting proposal will undermine: Patient access to medicines
July 26, 2022
Survey Says: Prescription drug prices are not fueling inflation concerns for Americans
July 22, 2022
Putting patients first at the state level — A conversation with Mark Reisenauer, President of Astellas Pharma US
July 14, 2022
By the Numbers: Patients lose when the government sets prices
July 8, 2022
Patients win as West Virginia implements first-in-nation share the savings policy
July 8, 2022
3 things voters are concerned about when it comes to their health care coverage
July 7, 2022
Prescription drug prices are not fueling inflation
July 6, 2022
Copay assistance is a lifeline for patients. So why are insurers blocking it?
June 29, 2022
Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines
June 16, 2022
Key takeaways from ASCO's annual meeting
June 10, 2022
New poll shows voters sounding the alarm on health insurance companies and PBMs
June 6, 2022
PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients
May 31, 2022
Report finds PBMs are increasingly restricting patient access to medicines
May 25, 2022
ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free
May 25, 2022
Report: More than 500 medicines in development to treat disorders of the blood
May 18, 2022
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
May 13, 2022
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
May 9, 2022
Annual projections from NHE compared to actual health care spending
May 5, 2022
Study finds insurance barriers disproportionately burden patients with chronic illness
May 4, 2022
What’s really happening when it comes to prescription drug costs
April 27, 2022
5 public opinion polling trends to watch
April 22, 2022
Analysis: States can help patients save nearly $1,000 annually on their medicines
April 21, 2022
New analysis confirms hospitals markup prices for oncology therapies
April 21, 2022
How standardized plans can improve patients’ access to medicines
April 18, 2022
The patient experience: Uncovering the barriers to care for insured Americans
March 28, 2022
Correcting the record: Putting medicine costs and spending in context
March 24, 2022
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
March 16, 2022
Guest Post: If we truly want to cure complex diseases, politicians should reject price setting
March 14, 2022
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
March 11, 2022
If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?
March 8, 2022
The patient experience: Insurance barriers continue to impede access to health care, especially among the country’s underserved
February 28, 2022
4 things to know about biopharmaceutical efforts to fight cancer
February 24, 2022
Government price setting leaves behind families counting on new medicines
February 23, 2022
340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients
February 8, 2022
Medicaid 101: Three charts on access and spending
February 3, 2022
Government price setting won’t stop insurers from shifting costs to patients
February 2, 2022
Research and development continues long after a medicine is initially approved
February 1, 2022
New comments outline ways to counteract cost-shifting insurance trends
January 28, 2022
Patients need to pay less for their medicines. States can help.
January 26, 2022
It’s a new year, but sadly Congress is still pursuing flawed price setting policies
January 25, 2022
New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”
January 25, 2022
CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings
January 21, 2022
New data show continued decline in death rates for cancer patients related to treatment advances
January 20, 2022
New study finds more than half of brand medicine spending goes to the supply chain and others
January 7, 2022
New NHE data show the true picture of health care spending
December 22, 2021
Making medicines more affordable: Making insurance work like insurance
December 8, 2021
3 things to know about the importance of post-approval research and development
December 6, 2021
Guest post: Congress should not put future innovation at risk
November 29, 2021
Insurance design barriers can impact patient adherence and can lead to poor health outcomes
November 23, 2021
What is missing in the current drug pricing plan
November 23, 2021
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
November 19, 2021
Making medicines more affordable: Sharing savings at the pharmacy counter
November 19, 2021
Three things to know about so-called Medicare negotiation polling
November 18, 2021
In the current health care debate, Congress has lost sight of what matters to U.S. voters
November 15, 2021
Making Medicines More Affordable: Making coupons count
November 5, 2021
What they are saying: Government price setting for medicines is not the answer
November 4, 2021
Four things to know from IQVIAs latest report
October 29, 2021
The patient experience: Insurance design hurdles lead to access issues for too many Americans
October 28, 2021
CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018
October 19, 2021
The patient experience: Out-of-pocket costs are driving patients affordability and access challenges
October 19, 2021
ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development
October 18, 2021
New poll shows Americans reject Medicare negotiation once they learn more about the policy
October 15, 2021
To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and health care system
October 14, 2021
What is Kaiser Family Foundation up to?
October 12, 2021
New report shows 3 in 10 Americans that have insurance still face a financial barrier to care
October 7, 2021
Industry leaders discuss the impact of the drug pricing debate
September 23, 2021
Five reasons tying VA prices to Medicare Part D misses the mark
September 22, 2021
America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach
September 15, 2021
Recognizing National Immunization Awareness Month
August 31, 2021
ICYMI: Event spotlights how we can make Medicare work better for patients
August 4, 2021
The future of the rebate rule: Will policymakers stand with patients?
August 2, 2021
Celebrating Medicare’s 56th anniversary
July 30, 2021
Recognizing Hepatitis R&D on World Hepatitis Day
July 28, 2021
340B hospitals among those that provide lowest levels of community benefit across the country
July 27, 2021
3 factors impacting medication adherence for patients with diabetes
July 20, 2021
New reports shed light on key facts about medicines and affordability
June 8, 2021
Out-of-pocket trends in Medicare Part D show rising costs for seniors
May 24, 2021
How strengthening the biosimilar marketplace benefits patients
May 18, 2021
Study finds nearly half of payers believe innovative contracts can lead to lower patient out-of-pocket costs
May 17, 2021
New report demonstrates development of new medicines relies on private sector expertise and investment
May 10, 2021
New data from insurers show detriments of copay accumulator adjustment programs
April 28, 2021
West Virginia becomes the first state to lower patient costs by sharing the savings
April 20, 2021
Getting the 340B program back on track in 2021
March 10, 2021
Nearly 40% of commercially insured patients face half their annual out-of-pocket expenses from just one health care encounter
March 2, 2021
Top five issues voters want addressed in the administration’s first 100 days
February 18, 2021
Action needed to preserve the six protected classes
February 3, 2021
Insurers shift medicine costs to patients with severe chronic illnesses
February 1, 2021
The latest misleading “poll” on drug pricing
January 28, 2021
The new Administration should reconsider a recent HHS rule that could negatively impact patient access and affordability
January 27, 2021
Election insights: Common ground areas to address Americans’ health care concerns
January 26, 2021
New insulin report highlights how incentives benefit middlemen, harm patients
January 22, 2021
ICYMI: Cancer death rate continues decline due to advances in treatment
January 19, 2021
Key facts: The final rebate rule will be a positive change for patients
January 19, 2021
New data show retail medicine prices fell in 2019
January 13, 2021
Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients
December 17, 2020